Dapagliflozin Ameliorates Doxorubicin-Induced Chemobrain and Cognitive Abnormalities in Rats: Modulation of AKT/GSK-3β and Wnt/β-Catenin Pathways
Neurochemical Research · 2025-10 · 50 (5)
DOI: 10.1007/s11064-025-04538-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemical Research, online erschienen am 05.09.2025. Verfasst von Gehad Farouk Abdelhafez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Pharmacy, October 6 University, Giza, Egypt. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Glucosides, Chemotherapy-Related Cognitive Impairment. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
Cognitive impairments are frequently observed in cancer survivors who received chemotherapy based on doxorubicin (DOX), attributable to oxidative stress, neuroinflammation, and the apoptotic effect of DOX. Dapagliflozin (DAPA) has gained significant attention attributable to its powerful anti-inflammatory, antioxidant, and anti-apoptotic characteristics. The present investigation seeks to assess the possible neuroprotective properties of DAPA in alleviating neurodegeneration and cognitive dysfunction caused by DOX. Chemobrain was induced by DOX (2 mg/kg, i.p.) once weekly for four weeks. Additionally, rats were treated with DAPA (2 mg/kg, p.o.) for 28 consecutive days. DAPA markedly mitigated behavioral deficits associated with cognitive impairment induced by DOX, as demonstrated by cognitive behavioral tests. Likewise, DAPA reversed histopathological abnormalities. Mechanistically, DAPA alleviated the oxidative stress induced by DOX by reducing tissue levels of NADPH oxidase 4 (NOX4) and malondialdehyde (MDA) while enhancing the activities of superoxide dismutase (SOD) and glutathione (GSH). Additionally, DAPA suppressed neuroinflammation by attenuating the production of interleukin-1β (IL-1β), tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa-B (NF-κB) in brain tissue, as well as the signaling pathways involved in apoptosis, including the Protein Kinase B (AKT)/Glycogen Synthase Kinase-3 beta (GSK-3β) pathway and the Wingless-related integration site (Wnt)/β-catenin pathway. Further evidence of DAPA’s anti-apoptotic effects was attributed to a decrease in the immunohistochemical expression of total caspase-3 and the p65 subunit of NF-κB (NF-κB-p65). DAPA induces neuroprotection against DOX-induced cognitive deterioration by providing antioxidant, anti-inflammatory, and anti-apoptotic effects. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochemistry Department, Faculty of Pharmacy, October 6 University, Giza, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, October 6 University, Giza, Egypt.
- Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt. Sara.mostafa@pharma.asu.edu.eg.
Förderung
- Ain Shams University
Zitieren
APA
Abdelhafez, G. F., Boshra, S. A., Abo-Zalam, H. B., & Radwan, S. M. (2025). Dapagliflozin Ameliorates Doxorubicin-Induced Chemobrain and Cognitive Abnormalities in Rats: Modulation of AKT/GSK-3β and Wnt/β-Catenin Pathways. Neurochemical Research, 50(5). https://doi.org/10.1007/s11064-025-04538-0
Vancouver
Abdelhafez GF, Boshra SA, Abo-Zalam HB, Radwan SM. Dapagliflozin Ameliorates Doxorubicin-Induced Chemobrain and Cognitive Abnormalities in Rats: Modulation of AKT/GSK-3β and Wnt/β-Catenin Pathways. Neurochemical Research. 2025;50(5). doi:10.1007/s11064-025-04538-0
BibTeX
@article{Abdelhafez2025,
author = {Abdelhafez, Gehad Farouk and Boshra, Sylvia A and Abo-Zalam, Hagar B and Radwan, Sara M},
title = {Dapagliflozin Ameliorates Doxorubicin-Induced Chemobrain and Cognitive Abnormalities in Rats: Modulation of AKT/GSK-3β and Wnt/β-Catenin Pathways},
journal = {Neurochemical Research},
year = {2025},
volume = {50},
number = {5},
doi = {10.1007/s11064-025-04538-0}
}
EUVIMED